Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

Holly A. Garriock, Michael Tanowitz, Jeffrey B. Kraft, Vu C. Dang, Eric J. Peters, Greg D. Jenkins, Megan S. Reinalda, Patrick J. McGrath, Mark Von Zastrow, Susan L Slager, Steven P. Hamilton

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: Because previous preclinical and clinical studies have implicated the endogenous opioid system in major depression and in the neurochemical action of antidepressants, the authors examined how DNA variation in the μ-opioid receptor gene may influence population variation in response to citalopram treatment. Method: A total of 1,953 individuals from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were treated with citalopram and genotyped for 53 single nucleotide polymorphisms (SNPs) in a 100-kb region of the OPRM1 gene. The sample consisted of Non-Hispanic Caucasians, Hispanic Caucasians, and African Americans. Population stratification was corrected using 119 ancestry informative markers and principal components analysis. Markers were tested for association with phenotypes for general and specific citalopram response as well as remission. Results: Association between one SNP and specific citalopram response was observed. After Bonferroni correction, the strongest finding was the association between the rs540825 SNP and specific response. The rs540825 polymorphism is a nonsynonymous SNP in the final exon of the m-opioid receptor-1X isoform of the OPRM1 gene, resulting in a histidine to glutamine change in the intracellular domain of the receptor. When Hispanic and Non-Hispanic Caucasians were analyzed separately, similar results in the population-corrected analyses were detected. Conclusions: These results suggest that rates of response to antidepressants and consequent remission from major depressive disorder are influenced by variation in the μ-opioid receptor gene as a result of either an effect on placebo response or true pharmacologic response.

Original languageEnglish (US)
Pages (from-to)565-573
Number of pages9
JournalAmerican Journal of Psychiatry
Volume167
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Citalopram
mu Opioid Receptor
Major Depressive Disorder
Single Nucleotide Polymorphism
Opioid Receptors
Hispanic Americans
Antidepressive Agents
Genes
Depression
Population
Placebo Effect
Therapeutics
Principal Component Analysis
Glutamine
Histidine
African Americans
Opioid Analgesics
Exons
Protein Isoforms
Phenotype

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Garriock, H. A., Tanowitz, M., Kraft, J. B., Dang, V. C., Peters, E. J., Jenkins, G. D., ... Hamilton, S. P. (2010). Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. American Journal of Psychiatry, 167(5), 565-573. https://doi.org/10.1176/appi.ajp.2009.08081167

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. / Garriock, Holly A.; Tanowitz, Michael; Kraft, Jeffrey B.; Dang, Vu C.; Peters, Eric J.; Jenkins, Greg D.; Reinalda, Megan S.; McGrath, Patrick J.; Von Zastrow, Mark; Slager, Susan L; Hamilton, Steven P.

In: American Journal of Psychiatry, Vol. 167, No. 5, 05.2010, p. 565-573.

Research output: Contribution to journalArticle

Garriock, HA, Tanowitz, M, Kraft, JB, Dang, VC, Peters, EJ, Jenkins, GD, Reinalda, MS, McGrath, PJ, Von Zastrow, M, Slager, SL & Hamilton, SP 2010, 'Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder', American Journal of Psychiatry, vol. 167, no. 5, pp. 565-573. https://doi.org/10.1176/appi.ajp.2009.08081167
Garriock, Holly A. ; Tanowitz, Michael ; Kraft, Jeffrey B. ; Dang, Vu C. ; Peters, Eric J. ; Jenkins, Greg D. ; Reinalda, Megan S. ; McGrath, Patrick J. ; Von Zastrow, Mark ; Slager, Susan L ; Hamilton, Steven P. / Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. In: American Journal of Psychiatry. 2010 ; Vol. 167, No. 5. pp. 565-573.
@article{b1a96a33156e4c809fdf6d777fa66d48,
title = "Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder",
abstract = "Objective: Because previous preclinical and clinical studies have implicated the endogenous opioid system in major depression and in the neurochemical action of antidepressants, the authors examined how DNA variation in the μ-opioid receptor gene may influence population variation in response to citalopram treatment. Method: A total of 1,953 individuals from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were treated with citalopram and genotyped for 53 single nucleotide polymorphisms (SNPs) in a 100-kb region of the OPRM1 gene. The sample consisted of Non-Hispanic Caucasians, Hispanic Caucasians, and African Americans. Population stratification was corrected using 119 ancestry informative markers and principal components analysis. Markers were tested for association with phenotypes for general and specific citalopram response as well as remission. Results: Association between one SNP and specific citalopram response was observed. After Bonferroni correction, the strongest finding was the association between the rs540825 SNP and specific response. The rs540825 polymorphism is a nonsynonymous SNP in the final exon of the m-opioid receptor-1X isoform of the OPRM1 gene, resulting in a histidine to glutamine change in the intracellular domain of the receptor. When Hispanic and Non-Hispanic Caucasians were analyzed separately, similar results in the population-corrected analyses were detected. Conclusions: These results suggest that rates of response to antidepressants and consequent remission from major depressive disorder are influenced by variation in the μ-opioid receptor gene as a result of either an effect on placebo response or true pharmacologic response.",
author = "Garriock, {Holly A.} and Michael Tanowitz and Kraft, {Jeffrey B.} and Dang, {Vu C.} and Peters, {Eric J.} and Jenkins, {Greg D.} and Reinalda, {Megan S.} and McGrath, {Patrick J.} and {Von Zastrow}, Mark and Slager, {Susan L} and Hamilton, {Steven P.}",
year = "2010",
month = "5",
doi = "10.1176/appi.ajp.2009.08081167",
language = "English (US)",
volume = "167",
pages = "565--573",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "5",

}

TY - JOUR

T1 - Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

AU - Garriock, Holly A.

AU - Tanowitz, Michael

AU - Kraft, Jeffrey B.

AU - Dang, Vu C.

AU - Peters, Eric J.

AU - Jenkins, Greg D.

AU - Reinalda, Megan S.

AU - McGrath, Patrick J.

AU - Von Zastrow, Mark

AU - Slager, Susan L

AU - Hamilton, Steven P.

PY - 2010/5

Y1 - 2010/5

N2 - Objective: Because previous preclinical and clinical studies have implicated the endogenous opioid system in major depression and in the neurochemical action of antidepressants, the authors examined how DNA variation in the μ-opioid receptor gene may influence population variation in response to citalopram treatment. Method: A total of 1,953 individuals from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were treated with citalopram and genotyped for 53 single nucleotide polymorphisms (SNPs) in a 100-kb region of the OPRM1 gene. The sample consisted of Non-Hispanic Caucasians, Hispanic Caucasians, and African Americans. Population stratification was corrected using 119 ancestry informative markers and principal components analysis. Markers were tested for association with phenotypes for general and specific citalopram response as well as remission. Results: Association between one SNP and specific citalopram response was observed. After Bonferroni correction, the strongest finding was the association between the rs540825 SNP and specific response. The rs540825 polymorphism is a nonsynonymous SNP in the final exon of the m-opioid receptor-1X isoform of the OPRM1 gene, resulting in a histidine to glutamine change in the intracellular domain of the receptor. When Hispanic and Non-Hispanic Caucasians were analyzed separately, similar results in the population-corrected analyses were detected. Conclusions: These results suggest that rates of response to antidepressants and consequent remission from major depressive disorder are influenced by variation in the μ-opioid receptor gene as a result of either an effect on placebo response or true pharmacologic response.

AB - Objective: Because previous preclinical and clinical studies have implicated the endogenous opioid system in major depression and in the neurochemical action of antidepressants, the authors examined how DNA variation in the μ-opioid receptor gene may influence population variation in response to citalopram treatment. Method: A total of 1,953 individuals from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were treated with citalopram and genotyped for 53 single nucleotide polymorphisms (SNPs) in a 100-kb region of the OPRM1 gene. The sample consisted of Non-Hispanic Caucasians, Hispanic Caucasians, and African Americans. Population stratification was corrected using 119 ancestry informative markers and principal components analysis. Markers were tested for association with phenotypes for general and specific citalopram response as well as remission. Results: Association between one SNP and specific citalopram response was observed. After Bonferroni correction, the strongest finding was the association between the rs540825 SNP and specific response. The rs540825 polymorphism is a nonsynonymous SNP in the final exon of the m-opioid receptor-1X isoform of the OPRM1 gene, resulting in a histidine to glutamine change in the intracellular domain of the receptor. When Hispanic and Non-Hispanic Caucasians were analyzed separately, similar results in the population-corrected analyses were detected. Conclusions: These results suggest that rates of response to antidepressants and consequent remission from major depressive disorder are influenced by variation in the μ-opioid receptor gene as a result of either an effect on placebo response or true pharmacologic response.

UR - http://www.scopus.com/inward/record.url?scp=77951778072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951778072&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2009.08081167

DO - 10.1176/appi.ajp.2009.08081167

M3 - Article

C2 - 20194481

AN - SCOPUS:77951778072

VL - 167

SP - 565

EP - 573

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 5

ER -